Contributions
Abstract: P910
Type: Poster
Abstract Category: Clinical aspects of MS - Economic burden
Background: People with Multiple Sclerosis (PwMS) and prescribers have multiple treatment choices. Disease modifying therapy (DMT) non-adherence and delaying DMT initiation impact outcomes. PwMS DMT non-adherence might increase long-term economic costs. Adherence can be measured by direct observation, patient report, prescription refills and other measures. With varied DMT route and frequency, “predicted PwMS adherence behavior” for self-administered treatments needs investigation to evaluate how this might impact prescribing practice and MS care. The Morisky Medication Adherence Score (MMAS-8), a validated 8 point questionnaire, is predictive of medication adherence, pharmacy fill data, relevant for treatments of varied routes/frequency, and correlates with efficacy and economic outcomes. DMT choice reflects many factors but adherence directly impacts therapy efficacy and perhaps safety. The long term MS economic impact demands treatment safety, efficacy, and adherence.
Objective: Explore PwMS predicted adherence behavior to medication if self-administered.
Methods: Single site cross sectional analysis of PwMS who completed Morisky Medication Adherence questionnaire (MMAS-8) during routine care.
Results: 788 PwMS, 73% female, average age 48. Predicted self-administered adherence behaviors for treatments were: 38% high, 34% medium, and 28% low adherence. The difference in predicted adherence behavior was significant (p< 0.01). Gender and age by themselves had no significant impact on predicted adherence profile. Prescribed DMT route did not appear to impact overall predicted PwMS self-administered adherence profile.
Conclusions: Patient adherence is a significant problem in MS care. Reduced DMT efficacy might reflect sub-optimal adherence for those self-administered treatments. High potency DMT, requiring safety monitoring, might have sub-optimal patient adherence. High frequency prescribed self-administered DMT prescribed to PwMS who are likely low adherent might reflect a poor choice of available DMT options. Treatment required for chronic disease requires ongoing efficacy, tolerability and high adherence. Analysis of individual adherence behavior might impact treatment decisions and alter DMT choices. Factors improving adherence or DMT choice might improve efficacy/outcome and reduce long term care costs.
Disclosure: All: nothing to disclose
Abstract: P910
Type: Poster
Abstract Category: Clinical aspects of MS - Economic burden
Background: People with Multiple Sclerosis (PwMS) and prescribers have multiple treatment choices. Disease modifying therapy (DMT) non-adherence and delaying DMT initiation impact outcomes. PwMS DMT non-adherence might increase long-term economic costs. Adherence can be measured by direct observation, patient report, prescription refills and other measures. With varied DMT route and frequency, “predicted PwMS adherence behavior” for self-administered treatments needs investigation to evaluate how this might impact prescribing practice and MS care. The Morisky Medication Adherence Score (MMAS-8), a validated 8 point questionnaire, is predictive of medication adherence, pharmacy fill data, relevant for treatments of varied routes/frequency, and correlates with efficacy and economic outcomes. DMT choice reflects many factors but adherence directly impacts therapy efficacy and perhaps safety. The long term MS economic impact demands treatment safety, efficacy, and adherence.
Objective: Explore PwMS predicted adherence behavior to medication if self-administered.
Methods: Single site cross sectional analysis of PwMS who completed Morisky Medication Adherence questionnaire (MMAS-8) during routine care.
Results: 788 PwMS, 73% female, average age 48. Predicted self-administered adherence behaviors for treatments were: 38% high, 34% medium, and 28% low adherence. The difference in predicted adherence behavior was significant (p< 0.01). Gender and age by themselves had no significant impact on predicted adherence profile. Prescribed DMT route did not appear to impact overall predicted PwMS self-administered adherence profile.
Conclusions: Patient adherence is a significant problem in MS care. Reduced DMT efficacy might reflect sub-optimal adherence for those self-administered treatments. High potency DMT, requiring safety monitoring, might have sub-optimal patient adherence. High frequency prescribed self-administered DMT prescribed to PwMS who are likely low adherent might reflect a poor choice of available DMT options. Treatment required for chronic disease requires ongoing efficacy, tolerability and high adherence. Analysis of individual adherence behavior might impact treatment decisions and alter DMT choices. Factors improving adherence or DMT choice might improve efficacy/outcome and reduce long term care costs.
Disclosure: All: nothing to disclose